These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24672057)

  • 1. Nedd8-activating enzyme inhibitor MLN4924 provides synergy with mitomycin C through interactions with ATR, BRCA1/BRCA2, and chromatin dynamics pathways.
    Garcia K; Blank JL; Bouck DC; Liu XJ; Sappal DS; Hather G; Cosmopoulos K; Thomas MP; Kuranda M; Pickard MD; Liu R; Bandi S; Smith PG; Lightcap ES
    Mol Cancer Ther; 2014 Jun; 13(6):1625-35. PubMed ID: 24672057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
    Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924.
    Blank JL; Liu XJ; Cosmopoulos K; Bouck DC; Garcia K; Bernard H; Tayber O; Hather G; Liu R; Narayanan U; Milhollen MA; Lightcap ES
    Cancer Res; 2013 Jan; 73(1):225-34. PubMed ID: 23100467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924.
    Jazaeri AA; Shibata E; Park J; Bryant JL; Conaway MR; Modesitt SC; Smith PG; Milhollen MA; Berger AJ; Dutta A
    Mol Cancer Ther; 2013 Oct; 12(10):1958-67. PubMed ID: 23939375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies.
    Kuo KL; Ho IL; Shi CS; Wu JT; Lin WC; Tsai YC; Chang HC; Chou CT; Hsu CH; Hsieh JT; Chang SC; Pu YS; Huang KH
    Cancer Lett; 2015 Jul; 363(2):127-36. PubMed ID: 25615422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
    Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
    Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib.
    Yang Z; Zhang J; Lin X; Wu D; Li G; Zhong C; Fang L; Jiang P; Yin L; Zhang L; Bie P; Xie CM
    Oncol Rep; 2019 Jun; 41(6):3257-3269. PubMed ID: 31002342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabine.
    Nawrocki ST; Kelly KR; Smith PG; Keaton M; Carraway H; Sekeres MA; Maciejewski JP; Carew JS
    Clin Cancer Res; 2015 Jan; 21(2):439-47. PubMed ID: 25388161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MLN4924 suppresses the BRCA1 complex and synergizes with PARP inhibition in NSCLC cells.
    Guo ZP; Hu YC; Xie Y; Jin F; Song ZQ; Liu XD; Ma T; Zhou PK
    Biochem Biophys Res Commun; 2017 Jan; 483(1):223-229. PubMed ID: 28034751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agents.
    Paiva C; Godbersen JC; Berger A; Brown JR; Danilov AV
    Cell Death Dis; 2015 Jul; 6(7):e1807. PubMed ID: 26158513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.
    Bahjat M; de Wilde G; van Dam T; Maas C; Bloedjes T; Bende RJ; van Noesel CJM; Luijks DM; Eldering E; Kersten MJ; Guikema JEJ
    Cell Cycle; 2019 Sep; 18(18):2307-2322. PubMed ID: 31349760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924.
    Liao H; Liu XJ; Blank JL; Bouck DC; Bernard H; Garcia K; Lightcap ES
    Mol Cell Proteomics; 2011 Nov; 10(11):M111.009183. PubMed ID: 21873567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.
    Wei D; Li H; Yu J; Sebolt JT; Zhao L; Lawrence TS; Smith PG; Morgan MA; Sun Y
    Cancer Res; 2012 Jan; 72(1):282-93. PubMed ID: 22072567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NEDD8-activating enzyme inhibition with MLN4924 sensitizes human cancer cells of different origins to apoptosis and necroptosis.
    El-Mesery M; Anany MA; Hazem SH; Shaker ME
    Arch Biochem Biophys; 2020 Sep; 691():108513. PubMed ID: 32721435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment-emergent mutations in NAEβ confer resistance to the NEDD8-activating enzyme inhibitor MLN4924.
    Milhollen MA; Thomas MP; Narayanan U; Traore T; Riceberg J; Amidon BS; Bence NF; Bolen JB; Brownell J; Dick LR; Loke HK; McDonald AA; Ma J; Manfredi MG; Sells TB; Sintchak MD; Yang X; Xu Q; Koenig EM; Gavin JM; Smith PG
    Cancer Cell; 2012 Mar; 21(3):388-401. PubMed ID: 22439935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma.
    Ho IL; Kuo KL; Liu SH; Chang HC; Hsieh JT; Wu JT; Chiang CK; Lin WC; Tsai YC; Chou CT; Hsu CH; Pu YS; Shi CS; Huang KH
    Sci Rep; 2015 Nov; 5():16948. PubMed ID: 26592553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2.
    Chen X; Chen F; Ren Y; Weng G; Xu L; Xue X; Keng PC; Lee SO; Chen Y
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1471-1484. PubMed ID: 31020420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer.
    Li JA; Song C; Rong Y; Kuang T; Wang D; Xu X; Yuan J; Luo K; Qin B; Nowsheen S; Lou Z; Lou W
    Cell Cycle; 2018; 17(2):191-199. PubMed ID: 29157102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
    Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
    Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
    Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
    Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.